Literature DB >> 20457265

Canine bone marrow-derived mesenchymal stromal cells suppress alloreactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation.

Won Sik Lee1, Yasuhiro Suzuki, Scott S Graves, Mineo Iwata, G M Venkataraman, Marco Mielcarek, Laura J Peterson, Susumu Ikehara, Beverly Torok-Storb, Rainer Storb.   

Abstract

Stable mixed hematopoietic chimerism has been consistently established in dogs who were mildly immunosuppressed by 200 cGy of total body irradiation (TBI) before undergoing dog leukocyte antigen (DLA)-identical bone marrow (BM) transplantation and who received a brief course of immunosuppression with mycophenolate mofetil (28 days) and cyclosporine (35 days) after transplantation. However, when TBI was reduced from 200 to 100 cGy, grafts were nearly uniformly rejected within 3-12 weeks. Here, we asked whether stable engraftment could be accomplished after a suboptimal dose of 100 cGy TBI with host immunosuppression enhanced by donor-derived mesenchymal stromal cells (MSCs) given after transplantation. MSCs were cultured from BM cells and evaluated in vitro for antigen expression. They showed profound immunosuppressive properties in mixed lymphocyte reactions (MLRs) in a cell dose-dependent manner not restricted by DLA. MSC and lymphocyte contact was not required, indicating that immunosuppression was mediated by soluble factors. Prostaglandin E2 was increased in culture supernatant when MSCs were cocultured in MLRs. The addition of indomethacin restored lymphocyte proliferation in cultures containing MSCs. MSCs expressed CD10, CD13, CD29, CD44, CD73/SH-3, CD90/Thy-1, and CD106/VCAM-1. For in vivo studies, MSCs were injected on the day of BM grafting and on day 35, the day of discontinuation of posttransplantation cyclosporine. MSCs derived from the respective BM donors failed to avert BM graft rejection in 4 dogs who received DLA-identical grafts after nonmyeloablative conditioning with 100 cGy TBI in a time course not significantly different from that of control dogs not given MSCs. Although the MSCs displayed in vitro characteristics similar to those reported for MSCs from other species, their immunosuppressive qualities failed to sustain stable BM engraftment in vivo in this canine model.
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457265      PMCID: PMC3233364          DOI: 10.1016/j.bbmt.2010.04.016

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  51 in total

Review 1.  Immunomodulatory properties of mesenchymal stromal cells.

Authors:  Alma J Nauta; Willem E Fibbe
Journal:  Blood       Date:  2007-07-30       Impact factor: 22.113

Review 2.  Mesenchymal stem cells: the fibroblasts' new clothes?

Authors:  Muzlifah A Haniffa; Matthew P Collin; Christopher D Buckley; Francesco Dazzi
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

Review 3.  How do mesenchymal stromal cells exert their therapeutic benefit?

Authors:  E M Horwitz; M Dominici
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

4.  Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompatibility complex-matched amnion-derived mesenchymal stem cells.

Authors:  Tomomi Mizokami; Hiroko Hisha; Satoshi Okazaki; Takashi Takaki; Xiao-Li Wang; Chang-Ye Song; Qing Li; Junko Kato; Naoki Hosaka; Muneo Inaba; Hideharu Kanzaki; Susumu Ikehara
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

5.  Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats.

Authors:  Ali Emre Aksu; Elaine Horibe; Justin Sacks; Ryosuke Ikeguchi; Jeremy Breitinger; Merissa Scozio; Jignesh Unadkat; Maryam Feili-Hariri
Journal:  Clin Immunol       Date:  2008-04-02       Impact factor: 3.969

6.  Isolation of human mesenchymal stromal cells is more efficient by red blood cell lysis.

Authors:  P Horn; S Bork; A Diehlmann; T Walenda; V Eckstein; A D Ho; W Wagner
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

7.  Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium.

Authors:  M von Bonin; F Stölzel; A Goedecke; K Richter; N Wuschek; K Hölig; U Platzbecker; T Illmer; M Schaich; J Schetelig; A Kiani; R Ordemann; G Ehninger; M Schmitz; M Bornhäuser
Journal:  Bone Marrow Transplant       Date:  2008-09-29       Impact factor: 5.483

8.  Intensified postgrafting immunosuppression failed to assure long-term engraftment of dog leukocyte antigen-identical canine marrow grafts after 1 gray total body irradiation.

Authors:  Mohamed L Sorror; Wendy Leisenring; Marco Mielcarek; Frederic Baron; Razvan Diaconescu; William J Hogan; Scott S Graves; Rainer Storb
Journal:  Transplantation       Date:  2008-04-15       Impact factor: 4.939

9.  Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation.

Authors:  Tatyana B Prigozhina; Sofia Khitrin; Gregory Elkin; Osnat Eizik; Shoshana Morecki; Shimon Slavin
Journal:  Exp Hematol       Date:  2008-07-10       Impact factor: 3.084

10.  Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10.

Authors:  Seung-Ha Yang; Min-Jung Park; Il-Hee Yoon; Su-Young Kim; So-Hee Hong; Jin-Young Shin; Hye-Young Nam; Yong-Hee Kim; Bongi Kim; Chung-Gyu Park
Journal:  Exp Mol Med       Date:  2009-05-31       Impact factor: 8.718

View more
  27 in total

1.  Comparing high and low total body irradiation dose rates for minimum-intensity conditioning of dogs for dog leukocyte antigen-identical bone marrow grafts.

Authors:  Scott S Graves; Barry E Storer; Tiffany M Butts; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2013-08-28       Impact factor: 5.742

2.  Mixed chimerism renders residual host dendritic cells incapable of alloimmunization of the marrow donor in the canine model of allogeneic marrow transplantation.

Authors:  Steven L Rosinski; Scott S Graves; Deborah A Higginbotham; Rainer Storb
Journal:  Chimerism       Date:  2015-10-02

Review 3.  Immunomodulation by mesenchymal stem cells in veterinary species.

Authors:  Danielle D Carrade; Dori L Borjesson
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

4.  Antagonistic and agonistic anti-canine CD28 monoclonal antibodies: tools for allogeneic transplantation.

Authors:  Scott S Graves; Diane M Stone; Carol Loretz; Laura J Peterson; Marina Lesnikova; Billanna Hwang; George E Georges; Richard Nash; Rainer Storb
Journal:  Transplantation       Date:  2011-04-27       Impact factor: 4.939

5.  Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation.

Authors:  Marco Mielcarek; Rainer Storb; George E Georges; Ludmila Golubev; Alla Nikitine; Billanna Hwang; Richard A Nash; Beverly Torok-Storb
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-30       Impact factor: 5.742

6.  Mechanisms of Immune Suppression Utilized by Canine Adipose and Bone Marrow-Derived Mesenchymal Stem Cells.

Authors:  Lyndah Chow; Valerie Johnson; Jonathan Coy; Dan Regan; Steven Dow
Journal:  Stem Cells Dev       Date:  2017-01-24       Impact factor: 3.272

Review 7.  Mesenchymal stromal cells: a new tool against graft-versus-host disease?

Authors:  Frédéric Baron; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-29       Impact factor: 5.742

8.  Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.

Authors:  Masahiko Sato; Rainer Storb; Carol Loretz; Diane Stone; Marco Mielcarek; George E Sale; Andrew R Rezvani; Scott S Graves
Journal:  Transplantation       Date:  2013-07-15       Impact factor: 4.939

9.  Safety of treatment with DLA-identical or unrelated mesenchymal stromal cells in DLA-identical canine bone marrow transplantation.

Authors:  Brian Kornblit; Wendy M Leisenring; Erlinda B Santos; Rainer Storb; Brenda M Sandmaier
Journal:  Chimerism       Date:  2013-05-29

10.  Markers for characterization of bone marrow multipotential stromal cells.

Authors:  Sally A Boxall; Elena Jones
Journal:  Stem Cells Int       Date:  2012-05-14       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.